Phoslo and Mesna drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Phoslo (calcium acetate) and Mesna (mesna). Common drug interactions include nephrogenic systemic fibrosis among males.

The phase IV clinical study analyzes what interactions people have when they take Phoslo and Mesna. It is created by eHealthMe based on reports of 14 people who take the same drugs from the FDA, and is updated regularly.

What is Phoslo?

Phoslo has active ingredients of calcium acetate. eHealthMe is studying from 4,291 Phoslo users. Check the latest studies of Phoslo.

What is Mesna?

Mesna has active ingredients of mesna. eHealthMe is studying from 9,647 Mesna users. Check the latest studies of Mesna.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Sep, 04, 2026

14 people who take Phoslo and Mesna together, and have interactions are studied.

What are the common drug interactions of Phoslo and Mesna, by gender? *:

female:

n/a

male:

Nephrogenic systemic fibrosis (involves fibrosis of skin, joints, eyes due to kidney disease)
Cardiac arrest
Skin tightness
Subcutaneous nodule
Xerosis (abnormal dryness of the skin or mucus membranes)
Endocardial fibrosis (cardiac fibrosis refers to an abnormal thickening of the heart valves)
Joint contracture (a permanent shortening of a muscle or joint)
Pain
Skin fibrosis (fibrous tissue formation on skin)
Discomfort

What are the common drug interactions of Phoslo and Mesna, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

Fibrosis (formation of excess fibrous connective tissue in an organ or tissue)
Metaplasia (change in the type of adult cells in a tissue to a form abnormal for that tissue)
Mobility decreased (ability to move is reduced)
Muscle contracture (a permanent shortening of a muscle)
Myocardial fibrosis (a condition in which the heart's muscle cells are impaired)
Pain in extremity
Pulmonary fibrosis (formation or development of excess fibrous connective tissue (fibrosis) in the lungs)
Skin induration (an abnormally hard spot or area on the skin)
Skin tightness
Subcutaneous nodule

20-29:

n/a

30-39:

Alanine aminotransferase increased
Aspartate aminotransferase increased
Nausea (feeling of having an urge to vomit)
Pneumonia fungal
Pseudomonas infection (pseudomonas infection is caused by a bacterium, pseudomonas aeruginosa)
Rash

40-49:

n/a

50-59:

n/a

60+:

Hypophosphataemia (electrolyte disturbance in which there is an abnormally low level of phosphate in the blood)
Neutrophil count decreased (less than normal number of neutrophil a type of blood cell)

What are the existing conditions these people have? *

Catheter Related Complication: 8 people, 57.14%
Joint Pain: 8 people, 57.14%
Convulsion (muscles contract and relax rapidly and repeatedly, resulting in an uncontrolled shaking of the body): 5 people, 35.71%
Blood Calcium Decreased: 3 people, 21.43%
High Blood Pressure: 3 people, 21.43%
Nuclear Magnetic Resonance Imaging Brain: 3 people, 21.43%
Anaemia (lack of blood): 3 people, 21.43%
Chronic Renal Failure (kidney failure): 3 people, 21.43%
Renal Osteodystrophy (a bone disease occurs when the kidneys fail to maintain the proper levels of calcium and phosphorus in the blood): 2 people, 14.29%
Hypercalcaemia (elevated calcium (ca+) level in the blood): 2 people, 14.29%

* Approximation only. Some reports may have incomplete information.

Do you take Phoslo and Mesna?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously